media-55-press-release-sema4-and-viecure-announce-strategic-collaboration-to-accelerate-precision-oncology-care

SEMA4 PRESS RELEASE | 03.02.20

Sema4 and VieCure Announce Strategic Collaboration to Accelerate Precision Oncology Care

Sema4, a patient-centered health intelligence company, and VieCure, an artificial intelligence (AI) informatics company with a leading point-of-care clinical decision support platform and a comprehensive electronic medical record (EMR) in oncology, today announced a strategic collaboration designed to help oncologists deliver personalized care and treatment to their patients.

media-54-Sema4-Participates-in-Governor’s-Innovation-Fellowship

Governor’s Innovation Fellowship in Connecticut | 02.24.20

Sema4 Participates in Governor’s Innovation Fellowship

Sema4 is one of nine companies participating in the Governor’s Innovation Fellowship in Connecticut. The office of Connecticut Governor Ned Lamont issued a press release on the Fellowship, a pilot program enabling college graduates to start their careers with a job at select growing companies, including Sema4. The announcement referenced Sema4 as “the fastest-growing health intelligence company in the country.”

media-53-moving-the-diagnostics-needle-for-personalized-care

CLINICAL OMICS | 02.11.20

Moving the Diagnostics Needle for Personalized Care

Clinical OMICs featured comments that Eric Schadt, Ph.D., Founder and CEO of Sema4, made in a recent panel discussion titled “Transformative Technologies: Previewing the Value Proposition and Outlook for Disruptive Tools Designed to Enable Personalized Medicine.” The panel was chaired and moderated by Michael Pellini, M.D., a member of Sema4’s Board of Directors. At Sema4, “the focus is on developing actionable data from patients, while also keeping the patient in control of their own health data,” shared Eric. Read the full article below by Chris Anderson, Editor-in-Chief at Clinical Omics.

media-52-sema4-appoints-biotech-leader-joel-sendek-as-chief-financial-officer

SEMA4 PRESS RELEASE | 11.14.19

Sema4 Appoints Biotech Leader Joel Sendek as Chief Financial Officer

Sema4 announces the appointment of Joel Sendek as Chief Financial Officer. Mr. Sendek has more than 25 years of financial leadership experience in the pharmaceutical and biotechnology sector, including overseeing the successful initial public offerings at his last two companies.

media-51-sema4-applies-data-driven-approach-to-expanded-carrier-screening

SEMA4 PRESS RELEASE | 10.11.19

Sema4 Applies Data-Driven Approach to Expanded Carrier Screening

Sema4 Applies Data-Driven Approach to Expanded Carrier Screening, and Will Soon Utilize Exome Sequencing for Genetic Testing Powered by the Centrellis™ Health Intelligence Platform, Sema4’s Expanded Carrier Screen with Personalized Residual Risk Will Help Inform Pregnancy Planning Decisions.